HRS 2024 — Prof Isabel Deisenhofer (German Heart Center Munich, Technical University of Munich, DE), investigator, joins us to discuss the findings from the TAILORED-AF trial (NCT04702451, Volta Medical).

This randomised controlled trial compared a tailored ablation strategy targeting areas of patio-temporal dispersion in combination with pulmonary vein isolation (PVI) to anatomical ablation strategy targeting PVI alone in patients with persistent atrial fibrillation (AF).

Questions
1. What is the background of this trial?
2. What is the Volta’s AF-Xplorer™ system?
3. What was the study design, eligibility criteria and outcome measures?
4. What findings did you present at HRS?
5. What are the next steps?

Support: This is independent content produced by Radcliffe Cardiology.

Interviewer: Mirjam Boros
Videographer: Dan Brent